Glaukos (GKOS) vs Penumbra (PEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Glaukos (GKOS) has outperformed Penumbra (PEN) over the past year, gaining 104.8% versus a gain of 27.0%. Over five years, GKOS leads with a +284.2% price change compared with +18.2% for PEN. Penumbra is the larger company by market cap ($12.49 billion vs $9.34 billion), about 1.3 times the size, while Glaukos is growing revenue faster (+32.3% vs +17.5%).
On valuation, Penumbra trades at a lower forward P/E (51.7x vs 302.4x for Glaukos). Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | PEN |
|---|---|---|
| Share price | $158.31 | $317.19 |
| Market cap | $9.34B | $12.49B |
| 1-day change | -8.06% | +0.26% |
| YTD return | +52.49% | +1.75% |
| 1-year return | +104.76% | +27.03% |
| 5-year return | +284.16% | +18.15% |
| P/E ratio (TTM) | — | 77.93 |
| Forward P/E | 302.37 | 51.73 |
| EPS (TTM) | $-3.26 | $4.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $507.44M | $1.40B |
| Revenue growth (YoY) | +32.33% | +17.50% |
| Net income (latest FY) | $-187.69M | $177.69M |
| Gross margin | 55.72% | 67.14% |
| Operating margin | -39.33% | 13.48% |
| Net margin | -36.99% | 12.66% |
| 52-week high | $191.62 | $362.41 |
| 52-week low | $73.16 | $221.26 |
| Distance from 52-week high | -17.38% | -12.48% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +25.51% | +14.00% |
| Average volume | 798.61K | 344.71K |
| Shares outstanding | 58.98M | 39.39M |
| Employees | 1,094 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GKOS has outperformed PEN by 77.7 percentage points over the past year.
- Penumbra is more profitable, keeping 12.7 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
- Glaukos grew revenue faster in its latest fiscal year (+32.33% vs +17.50%).
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
GKOS vs PEN FAQ
Which is bigger, Glaukos or Penumbra?
Penumbra (PEN) is larger, with a market capitalization of $12.49B compared with $9.34B for Glaukos (GKOS).
Which stock has performed better over the past year, GKOS or PEN?
GKOS returned +104.76% over the past 12 months, compared with +27.03% for PEN (price return, excluding dividends). Past performance does not predict future results.
Are Glaukos and Penumbra in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.